[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fUpit9PzbEu_fvYegPG23MOr_r2TarNdRqB3rQvq4fr0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":49,"rows":56},"Medical University Innsbruck",[4],178,false,47,7,260058,4,142,[14,17,19,21,24,26,28,30],{"name":15,"count":16},"COVID-19",6,{"name":18,"count":11},"Cardiovascular Diseases",{"name":20,"count":11},"Atherosclerosis",{"name":22,"count":23},"Heart Failure",3,{"name":25,"count":23},"Healthy",{"name":27,"count":23},"Covid19",{"name":29,"count":23},"Major Depressive Disorder",{"name":31,"count":32},"Coronary Artery Disease",2,[34,39,44],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT04095351","Connective Tissue Diseases and Lung Manifestations","2021-03-01","Blood sampling",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04875585","Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab\u002FLenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC","2023-12","neoadjuvant therapy with Pembrolizumab\u002FLenvatinib",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06582329","Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated Hepatitis","2025-07","Alfa1 Antitrypsin",[50,51,52,53,54,55],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[57,83,101,124,160,198,225,253,279,307,325,343,361,388,406,431,449,476,502,520,553,579,605,623,647,672,698,736,754,781,799,823,847,865,890,914,932,958,996,1014,1032,1050,1076,1104,1122,1147,1165,1191,1219,1237,1255,1283],{"intervention":43,"totalTrials":58,"cells":59},1,{"EARLY_PHASE1":60,"PHASE1":63,"PHASE2":65,"PHASE3":77,"PHASE4":79,"NA":81},{"trials":61,"activeCount":62},[],0,{"trials":64,"activeCount":62},[],{"trials":66,"activeCount":58,"soonestReadout":42},[67],{"nctId":40,"briefTitle":41,"status":68,"phases":69,"primaryCompletion":42,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":75},"RECRUITING",[52],"2027-12","2021-05-12",33,[74],"Non Small Cell Lung Cancer",[43,76],"Adjuvant Treatment Phase",{"trials":78,"activeCount":62},[],{"trials":80,"activeCount":62},[],{"trials":82,"activeCount":62},[],{"intervention":76,"totalTrials":58,"cells":84},{"EARLY_PHASE1":85,"PHASE1":87,"PHASE2":89,"PHASE3":95,"PHASE4":97,"NA":99},{"trials":86,"activeCount":62},[],{"trials":88,"activeCount":62},[],{"trials":90,"activeCount":58,"soonestReadout":42},[91],{"nctId":40,"briefTitle":41,"status":68,"phases":92,"primaryCompletion":42,"completion":70,"start":71,"enrollment":72,"conditions":93,"interventions":94},[52],[74],[43,76],{"trials":96,"activeCount":62},[],{"trials":98,"activeCount":62},[],{"trials":100,"activeCount":62},[],{"intervention":48,"totalTrials":58,"cells":102},{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":107,"PHASE3":118,"PHASE4":120,"NA":122},{"trials":104,"activeCount":62},[],{"trials":106,"activeCount":62},[],{"trials":108,"activeCount":58,"soonestReadout":47},[109],{"nctId":45,"briefTitle":46,"status":110,"phases":111,"primaryCompletion":47,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":117},"NOT_YET_RECRUITING",[52],"2026-12","2025-04",16,[116],"Alcohol-Associated Hepatitis",[48],{"trials":119,"activeCount":62},[],{"trials":121,"activeCount":62},[],{"trials":123,"activeCount":62},[],{"intervention":38,"totalTrials":32,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":136},{"trials":127,"activeCount":62},[],{"trials":129,"activeCount":62},[],{"trials":131,"activeCount":62},[],{"trials":133,"activeCount":62},[],{"trials":135,"activeCount":62},[],{"trials":137,"activeCount":58,"soonestReadout":37},[138,148],{"nctId":35,"briefTitle":36,"status":68,"phases":139,"primaryCompletion":37,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":147},[],"2034-10-01","2019-12-09",120,[144,145,146],"Connective Tissue Diseases","Interstitial Lung Disease","Systemic Sclerosis",[38],{"nctId":149,"briefTitle":150,"status":151,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":159},"NCT04416100","Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19)","UNKNOWN",[],"2022-04-28","2020-04-29",130,[157,158],"Covid-19","Pulmonary Fibrosis",[38],{"intervention":161,"totalTrials":32,"cells":162},"Cetuximab",{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":181,"PHASE4":183,"NA":196},{"trials":164,"activeCount":62},[],{"trials":166,"activeCount":62},[],{"trials":168,"activeCount":62},[169],{"nctId":170,"briefTitle":171,"status":151,"phases":172,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":179},"NCT01166035","Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors",[51,52],"2011-09","2011-12","2010-03",20,[178],"Solid Tumors",[180,161],"Lenalidomide",{"trials":182,"activeCount":62},[],{"trials":184,"activeCount":62},[185],{"nctId":186,"briefTitle":187,"status":188,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":11,"conditions":192,"interventions":194},"NCT02015650","Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck","TERMINATED",[54],"2016-04-19","2014-04",[193],"Head and Neck Neoplasms",[161,195],"Mitomycin-C\u002F 5-Fluorouracil",{"trials":197,"activeCount":62},[],{"intervention":199,"totalTrials":58,"cells":200},"organ perfusion with rabbit anti-thymocyte globulin",{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":223},{"trials":202,"activeCount":62},[],{"trials":204,"activeCount":62},[],{"trials":206,"activeCount":62},[],{"trials":208,"activeCount":62},[],{"trials":210,"activeCount":62},[211],{"nctId":212,"briefTitle":213,"status":214,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT03377283","Peri-operative rATG-perfusion of Solid Transplants","COMPLETED",[54],"2015-03-04","2016-02-24","2012-08-17",80,[221],"Organ Preservation Solutions",[199],{"trials":224,"activeCount":62},[],{"intervention":226,"totalTrials":58,"cells":227},"sustained-release bupropion",{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":251},{"trials":229,"activeCount":62},[],{"trials":231,"activeCount":62},[],{"trials":233,"activeCount":62},[],{"trials":235,"activeCount":62},[],{"trials":237,"activeCount":62},[238],{"nctId":239,"briefTitle":240,"status":214,"phases":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":250},"NCT00484692","Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation",[54],"2007-01","2005-07",779,[246,247,248,249],"Nicotine Dependence","Substance Abuse","Substance Dependence","Tobacco Dependence",[226],{"trials":252,"activeCount":62},[],{"intervention":254,"totalTrials":58,"cells":255},"ACE inhibitor, angiotensin receptor blocker",{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":277},{"trials":257,"activeCount":62},[],{"trials":259,"activeCount":62},[],{"trials":261,"activeCount":62},[],{"trials":263,"activeCount":62},[],{"trials":265,"activeCount":62},[266],{"nctId":267,"briefTitle":268,"status":214,"phases":269,"primaryCompletion":270,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NCT04353596","Stopping ACE-inhibitors in COVID-19",[54],"2021-02-16","2021-02-24","2020-04-20",216,[275,15],"SARS-CoV-2",[254],{"trials":278,"activeCount":62},[],{"intervention":280,"totalTrials":58,"cells":281},"propofol",{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":305},{"trials":283,"activeCount":62},[],{"trials":285,"activeCount":62},[],{"trials":287,"activeCount":62},[],{"trials":289,"activeCount":62},[],{"trials":291,"activeCount":62},[292],{"nctId":293,"briefTitle":294,"status":214,"phases":295,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":301},"NCT00706277","Effect of Total Intravenous Anesthesia and Balanced Anesthesia on Postoperative Lung Function",[54],"2008-12","2008-06",60,[300],"Lung Function",[280,280,302,303,304],"remifentanil","fentanyl","Sevoflurane\u002FNitrous Oxide",{"trials":306,"activeCount":62},[],{"intervention":302,"totalTrials":58,"cells":308},{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":317,"NA":323},{"trials":310,"activeCount":62},[],{"trials":312,"activeCount":62},[],{"trials":314,"activeCount":62},[],{"trials":316,"activeCount":62},[],{"trials":318,"activeCount":62},[319],{"nctId":293,"briefTitle":294,"status":214,"phases":320,"completion":296,"start":297,"enrollment":298,"conditions":321,"interventions":322},[54],[300],[280,280,302,303,304],{"trials":324,"activeCount":62},[],{"intervention":303,"totalTrials":58,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":341},{"trials":328,"activeCount":62},[],{"trials":330,"activeCount":62},[],{"trials":332,"activeCount":62},[],{"trials":334,"activeCount":62},[],{"trials":336,"activeCount":62},[337],{"nctId":293,"briefTitle":294,"status":214,"phases":338,"completion":296,"start":297,"enrollment":298,"conditions":339,"interventions":340},[54],[300],[280,280,302,303,304],{"trials":342,"activeCount":62},[],{"intervention":304,"totalTrials":58,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":359},{"trials":346,"activeCount":62},[],{"trials":348,"activeCount":62},[],{"trials":350,"activeCount":62},[],{"trials":352,"activeCount":62},[],{"trials":354,"activeCount":62},[355],{"nctId":293,"briefTitle":294,"status":214,"phases":356,"completion":296,"start":297,"enrollment":298,"conditions":357,"interventions":358},[54],[300],[280,280,302,303,304],{"trials":360,"activeCount":62},[],{"intervention":362,"totalTrials":58,"cells":363},"Dexamethasone",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":386},{"trials":365,"activeCount":62},[],{"trials":367,"activeCount":62},[],{"trials":369,"activeCount":62},[],{"trials":371,"activeCount":62},[],{"trials":373,"activeCount":62},[374],{"nctId":375,"briefTitle":376,"status":151,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":298,"conditions":380,"interventions":384},"NCT03700177","Ropivacaine 0,2% Plus Dexamethasone Versus Ropivacaine 0,2% Plus Placebo in Modified Pectoral Block",[54],"2020-12-31","2019-02-01",[381,382,383],"Effect of Drugs","Breast Pain","Anesthesia, Local",[362,385],"Ropivacaine Injection [Naropin]",{"trials":387,"activeCount":62},[],{"intervention":385,"totalTrials":58,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":398,"NA":404},{"trials":391,"activeCount":62},[],{"trials":393,"activeCount":62},[],{"trials":395,"activeCount":62},[],{"trials":397,"activeCount":62},[],{"trials":399,"activeCount":62},[400],{"nctId":375,"briefTitle":376,"status":151,"phases":401,"primaryCompletion":378,"completion":378,"start":379,"enrollment":298,"conditions":402,"interventions":403},[54],[381,382,383],[362,385],{"trials":405,"activeCount":62},[],{"intervention":407,"totalTrials":58,"cells":408},"Administration of platelet concentrate and taking blood samples",{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":417,"NA":429},{"trials":410,"activeCount":62},[],{"trials":412,"activeCount":62},[],{"trials":414,"activeCount":62},[],{"trials":416,"activeCount":62},[],{"trials":418,"activeCount":62},[419],{"nctId":420,"briefTitle":421,"status":214,"phases":422,"primaryCompletion":423,"completion":423,"start":424,"enrollment":155,"conditions":425,"interventions":428},"NCT01955811","Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion",[54],"2014-08","2012-12",[426,427],"Blood Platelet Transfusion","Blood Clotting",[407],{"trials":430,"activeCount":62},[],{"intervention":195,"totalTrials":58,"cells":432},{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":441,"NA":447},{"trials":434,"activeCount":62},[],{"trials":436,"activeCount":62},[],{"trials":438,"activeCount":62},[],{"trials":440,"activeCount":62},[],{"trials":442,"activeCount":62},[443],{"nctId":186,"briefTitle":187,"status":188,"phases":444,"primaryCompletion":190,"completion":190,"start":191,"enrollment":11,"conditions":445,"interventions":446},[54],[193],[161,195],{"trials":448,"activeCount":62},[],{"intervention":450,"totalTrials":58,"cells":451},"Dapagliflozin",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":474},{"trials":453,"activeCount":62},[],{"trials":455,"activeCount":62},[],{"trials":457,"activeCount":62},[],{"trials":459,"activeCount":62},[],{"trials":461,"activeCount":62},[462],{"nctId":463,"briefTitle":464,"status":214,"phases":465,"primaryCompletion":466,"completion":467,"start":423,"enrollment":468,"conditions":469,"interventions":473},"NCT02211742","Dapagliflozin in Type 1 Diabetes",[54],"2016-07-29","2017-02-08",12,[470,471,472],"Fasting Glucose","Glucose Excursion","Glycemic Control",[450],{"trials":475,"activeCount":62},[],{"intervention":477,"totalTrials":58,"cells":478},"NaCl 0.9%",{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":485,"PHASE4":487,"NA":500},{"trials":480,"activeCount":62},[],{"trials":482,"activeCount":62},[],{"trials":484,"activeCount":62},[],{"trials":486,"activeCount":62},[],{"trials":488,"activeCount":62},[489],{"nctId":490,"briefTitle":491,"status":214,"phases":492,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT02182999","Continuous Wound Infiltration After Hallux Valgus Surgery",[54],"2017-04","2014-05",50,[497],"Hallux Valgus",[477,499],"Ropivacaine 0.2%",{"trials":501,"activeCount":62},[],{"intervention":499,"totalTrials":58,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":518},{"trials":505,"activeCount":62},[],{"trials":507,"activeCount":62},[],{"trials":509,"activeCount":62},[],{"trials":511,"activeCount":62},[],{"trials":513,"activeCount":62},[514],{"nctId":490,"briefTitle":491,"status":214,"phases":515,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":516,"interventions":517},[54],[497],[477,499],{"trials":519,"activeCount":62},[],{"intervention":521,"totalTrials":32,"cells":522},"Nabilone 0.25 mg",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":539,"PHASE4":549,"NA":551},{"trials":524,"activeCount":62},[],{"trials":526,"activeCount":62},[],{"trials":528,"activeCount":62},[529],{"nctId":530,"briefTitle":531,"status":214,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":538},"NCT03769896","Nabilone for Non-motor Symptoms in Parkinson's Disease",[52],"2019-07-15","2017-10-03",48,[537],"Parkinson Disease",[521],{"trials":540,"activeCount":62},[541],{"nctId":542,"briefTitle":531,"status":214,"phases":543,"primaryCompletion":544,"completion":544,"start":545,"enrollment":546,"conditions":547,"interventions":548},"NCT03773796",[53],"2020-01-31","2018-08-06",22,[537],[521],{"trials":550,"activeCount":62},[],{"trials":552,"activeCount":62},[],{"intervention":554,"totalTrials":58,"cells":555},"MMPF",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":575,"NA":577},{"trials":557,"activeCount":62},[],{"trials":559,"activeCount":62},[],{"trials":561,"activeCount":62},[],{"trials":563,"activeCount":62},[564],{"nctId":565,"briefTitle":566,"status":151,"phases":567,"primaryCompletion":568,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":574},"NCT04335617","Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis",[53],"2023-02-26","2023-08-26","2020-02-26",200,[573],"Proctitis Radiation",[554],{"trials":576,"activeCount":62},[],{"trials":578,"activeCount":62},[],{"intervention":580,"totalTrials":58,"cells":581},"Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate",{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":588,"PHASE4":601,"NA":603},{"trials":583,"activeCount":62},[],{"trials":585,"activeCount":62},[],{"trials":587,"activeCount":62},[],{"trials":589,"activeCount":62},[590],{"nctId":591,"briefTitle":592,"status":188,"phases":593,"primaryCompletion":594,"completion":594,"start":595,"enrollment":596,"conditions":597,"interventions":599},"NCT01545635","RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma",[53],"2016-02","2012-03",100,[598],"Major Trauma",[580,600],"Fresh Frozen Plasma blood type 0, A, B and AB",{"trials":602,"activeCount":62},[],{"trials":604,"activeCount":62},[],{"intervention":600,"totalTrials":58,"cells":606},{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":613,"PHASE4":619,"NA":621},{"trials":608,"activeCount":62},[],{"trials":610,"activeCount":62},[],{"trials":612,"activeCount":62},[],{"trials":614,"activeCount":62},[615],{"nctId":591,"briefTitle":592,"status":188,"phases":616,"primaryCompletion":594,"completion":594,"start":595,"enrollment":596,"conditions":617,"interventions":618},[53],[598],[580,600],{"trials":620,"activeCount":62},[],{"trials":622,"activeCount":62},[],{"intervention":624,"totalTrials":58,"cells":625},"Levosimendan",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":643,"NA":645},{"trials":627,"activeCount":62},[],{"trials":629,"activeCount":62},[],{"trials":631,"activeCount":62},[],{"trials":633,"activeCount":62},[634],{"nctId":635,"briefTitle":636,"status":151,"phases":637,"primaryCompletion":638,"completion":638,"start":639,"enrollment":142,"conditions":640,"interventions":642},"NCT01065194","Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure",[53],"2011-08","2009-08",[641],"Chronic Stable Heart Failure",[624],{"trials":644,"activeCount":62},[],{"trials":646,"activeCount":62},[],{"intervention":648,"totalTrials":58,"cells":649},"Imiquimod 5% cream",{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":668,"NA":670},{"trials":651,"activeCount":62},[],{"trials":653,"activeCount":62},[],{"trials":655,"activeCount":62},[],{"trials":657,"activeCount":62},[658],{"nctId":659,"briefTitle":660,"status":151,"phases":661,"primaryCompletion":662,"completion":662,"start":663,"enrollment":571,"conditions":664,"interventions":667},"NCT03289260","Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial",[53],"2024-11-15","2021-11-15",[665,666],"Anogenital Human Papillomavirus Infection","Condyloma Anal",[648],{"trials":669,"activeCount":62},[],{"trials":671,"activeCount":62},[],{"intervention":673,"totalTrials":58,"cells":674},"Esketamine nasal spray",{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":694,"NA":696},{"trials":676,"activeCount":62},[],{"trials":678,"activeCount":62},[],{"trials":680,"activeCount":62},[],{"trials":682,"activeCount":62},[683],{"nctId":684,"briefTitle":685,"status":686,"phases":687,"primaryCompletion":688,"completion":689,"start":690,"enrollment":62,"conditions":691,"interventions":693},"NCT04924257","ECT vs. Esketamine","WITHDRAWN",[53],"2023-08","2024-04","2021-07-28",[692,29],"Treatment Resistant Depression",[673],{"trials":695,"activeCount":62},[],{"trials":697,"activeCount":62},[],{"intervention":699,"totalTrials":32,"cells":700},"liposome-encapsulated doxorubicin citrate",{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":730,"PHASE4":732,"NA":734},{"trials":702,"activeCount":62},[],{"trials":704,"activeCount":62},[],{"trials":706,"activeCount":62},[707,718],{"nctId":708,"briefTitle":709,"status":151,"phases":710,"primaryCompletion":711,"start":712,"enrollment":713,"conditions":714,"interventions":716},"NCT01100359","Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer",[52],"2010-10","2007-11",39,[715],"Endometrial Cancer",[717,699],"carboplatin",{"nctId":719,"briefTitle":720,"status":151,"phases":721,"primaryCompletion":494,"start":722,"enrollment":723,"conditions":724,"interventions":728},"NCT01100372","Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer",[52],"2009-07",154,[725,726,727],"Fallopian Tube Cancer","Ovarian Cancer","Primary Peritoneal Cavity Cancer",[729,699],"gemcitabine hydrochloride",{"trials":731,"activeCount":62},[],{"trials":733,"activeCount":62},[],{"trials":735,"activeCount":62},[],{"intervention":717,"totalTrials":58,"cells":737},{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":748,"PHASE4":750,"NA":752},{"trials":739,"activeCount":62},[],{"trials":741,"activeCount":62},[],{"trials":743,"activeCount":62},[744],{"nctId":708,"briefTitle":709,"status":151,"phases":745,"primaryCompletion":711,"start":712,"enrollment":713,"conditions":746,"interventions":747},[52],[715],[717,699],{"trials":749,"activeCount":62},[],{"trials":751,"activeCount":62},[],{"trials":753,"activeCount":62},[],{"intervention":755,"totalTrials":58,"cells":756},"Vaxzevria",{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":758,"activeCount":62},[],{"trials":760,"activeCount":62},[],{"trials":762,"activeCount":62},[763],{"nctId":764,"briefTitle":765,"status":151,"phases":766,"primaryCompletion":767,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":773},"NCT04907331","Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2",[52],"2021-11-30","2021-12-30","2021-05-10",3000,[772],"SARS-CoV2 Infection",[755,774],"Comirnaty",{"trials":776,"activeCount":62},[],{"trials":778,"activeCount":62},[],{"trials":780,"activeCount":62},[],{"intervention":774,"totalTrials":58,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":784,"activeCount":62},[],{"trials":786,"activeCount":62},[],{"trials":788,"activeCount":62},[789],{"nctId":764,"briefTitle":765,"status":151,"phases":790,"primaryCompletion":767,"completion":768,"start":769,"enrollment":770,"conditions":791,"interventions":792},[52],[772],[755,774],{"trials":794,"activeCount":62},[],{"trials":796,"activeCount":62},[],{"trials":798,"activeCount":62},[],{"intervention":800,"totalTrials":58,"cells":801},"Bevacizumab \u002F Irinotecan",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":817,"PHASE4":819,"NA":821},{"trials":803,"activeCount":62},[],{"trials":805,"activeCount":62},[],{"trials":807,"activeCount":62},[808],{"nctId":809,"briefTitle":810,"status":151,"phases":811,"primaryCompletion":812,"completion":812,"start":175,"enrollment":813,"conditions":814,"interventions":816},"NCT01144988","Avastin \u002F Irinotecan in Patients With Recurrent or Progressive Malignant Glioma",[52],"2013-03",35,[815],"Recurrent Malignant Glioma",[800],{"trials":818,"activeCount":62},[],{"trials":820,"activeCount":62},[],{"trials":822,"activeCount":62},[],{"intervention":824,"totalTrials":58,"cells":825},"panitumumab",{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":827,"activeCount":62},[],{"trials":829,"activeCount":62},[],{"trials":831,"activeCount":62},[832],{"nctId":833,"briefTitle":834,"status":151,"phases":835,"primaryCompletion":812,"start":836,"enrollment":495,"conditions":837,"interventions":839},"NCT01158248","Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer",[52],"2010-02",[838],"Cervical Cancer",[824,840],"cisplatin",{"trials":842,"activeCount":62},[],{"trials":844,"activeCount":62},[],{"trials":846,"activeCount":62},[],{"intervention":840,"totalTrials":58,"cells":848},{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":850,"activeCount":62},[],{"trials":852,"activeCount":62},[],{"trials":854,"activeCount":62},[855],{"nctId":833,"briefTitle":834,"status":151,"phases":856,"primaryCompletion":812,"start":836,"enrollment":495,"conditions":857,"interventions":858},[52],[838],[824,840],{"trials":860,"activeCount":62},[],{"trials":862,"activeCount":62},[],{"trials":864,"activeCount":62},[],{"intervention":866,"totalTrials":58,"cells":867},"Argatroban",{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":869,"activeCount":62},[],{"trials":871,"activeCount":62},[],{"trials":873,"activeCount":62},[874],{"nctId":875,"briefTitle":876,"status":214,"phases":877,"primaryCompletion":878,"completion":878,"start":879,"enrollment":880,"conditions":881,"interventions":883},"NCT01734252","Argatroban in Critically Ill Patients With Heparin Resistance",[52],"2016-04-01","2012-07-29",44,[882],"Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance",[866],{"trials":885,"activeCount":62},[],{"trials":887,"activeCount":62},[],{"trials":889,"activeCount":62},[],{"intervention":891,"totalTrials":58,"cells":892},"68Ga-DOTA-MGS5",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":894,"activeCount":62},[],{"trials":896,"activeCount":62},[],{"trials":898,"activeCount":62},[899],{"nctId":900,"briefTitle":901,"status":214,"phases":902,"primaryCompletion":903,"completion":903,"start":904,"enrollment":468,"conditions":905,"interventions":907},"NCT06155994","68Ga-DOTA-MGS5 PET\u002FCT in Patients With Advanced Neuroendocrine Tumours",[51,52],"2023-06-30","2021-01-20",[906],"Neuroendocrine Tumors",[891],{"trials":909,"activeCount":62},[],{"trials":911,"activeCount":62},[],{"trials":913,"activeCount":62},[],{"intervention":180,"totalTrials":58,"cells":915},{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":926,"PHASE4":928,"NA":930},{"trials":917,"activeCount":62},[],{"trials":919,"activeCount":62},[],{"trials":921,"activeCount":62},[922],{"nctId":170,"briefTitle":171,"status":151,"phases":923,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":924,"interventions":925},[51,52],[178],[180,161],{"trials":927,"activeCount":62},[],{"trials":929,"activeCount":62},[],{"trials":931,"activeCount":62},[],{"intervention":933,"totalTrials":58,"cells":934},"Human Fibrinogen Concentrate",{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":936,"activeCount":62},[],{"trials":938,"activeCount":62},[],{"trials":940,"activeCount":62},[941],{"nctId":942,"briefTitle":943,"status":214,"phases":944,"primaryCompletion":945,"completion":946,"start":173,"enrollment":947,"conditions":948,"interventions":951},"NCT01475344","Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC)",[51,52],"2015-10","2015-12",67,[949,950],"Trauma","Massive Hemorrhage",[933],{"trials":953,"activeCount":62},[],{"trials":955,"activeCount":62},[],{"trials":957,"activeCount":62},[],{"intervention":959,"totalTrials":58,"cells":960},"CVVH with Phoxilium® in the first 48h after randomization",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":990,"PHASE4":992,"NA":994},{"trials":962,"activeCount":62},[],{"trials":964,"activeCount":62},[],{"trials":966,"activeCount":62},[967],{"nctId":968,"briefTitle":969,"status":214,"phases":970,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":975,"interventions":986},"NCT04071171","Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation",[52],"2023-11-15","2024-03-11","2020-08-01",88,[976,977,978,979,980,981,982,983,984,985],"Critically Ill","Acute Kidney Injury","Renal Replacement Therapy","Continuous Renal Replacement Therapy","Continuous Veno-Venous Hemofiltration","Replacement Fluid","Phoxilium","Biphozyl","Anticoagulation","Regional Citrate Anticoagulation",[959,987,988,989],"CVVH with Biphozyl® in the first 48h after randomization","CVVH with Phoxilium® in the second 48h after randomization","CVVH with Biphozyl® in the second 48h after randomization",{"trials":991,"activeCount":62},[],{"trials":993,"activeCount":62},[],{"trials":995,"activeCount":62},[],{"intervention":987,"totalTrials":58,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":999,"activeCount":62},[],{"trials":1001,"activeCount":62},[],{"trials":1003,"activeCount":62},[1004],{"nctId":968,"briefTitle":969,"status":214,"phases":1005,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":1006,"interventions":1007},[52],[976,977,978,979,980,981,982,983,984,985],[959,987,988,989],{"trials":1009,"activeCount":62},[],{"trials":1011,"activeCount":62},[],{"trials":1013,"activeCount":62},[],{"intervention":988,"totalTrials":58,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1026,"PHASE4":1028,"NA":1030},{"trials":1017,"activeCount":62},[],{"trials":1019,"activeCount":62},[],{"trials":1021,"activeCount":62},[1022],{"nctId":968,"briefTitle":969,"status":214,"phases":1023,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":1024,"interventions":1025},[52],[976,977,978,979,980,981,982,983,984,985],[959,987,988,989],{"trials":1027,"activeCount":62},[],{"trials":1029,"activeCount":62},[],{"trials":1031,"activeCount":62},[],{"intervention":989,"totalTrials":58,"cells":1033},{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1035,"activeCount":62},[],{"trials":1037,"activeCount":62},[],{"trials":1039,"activeCount":62},[1040],{"nctId":968,"briefTitle":969,"status":214,"phases":1041,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":1042,"interventions":1043},[52],[976,977,978,979,980,981,982,983,984,985],[959,987,988,989],{"trials":1045,"activeCount":62},[],{"trials":1047,"activeCount":62},[],{"trials":1049,"activeCount":62},[],{"intervention":1051,"totalTrials":58,"cells":1052},"Sunitinib",{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1070,"PHASE4":1072,"NA":1074},{"trials":1054,"activeCount":62},[],{"trials":1056,"activeCount":62},[],{"trials":1058,"activeCount":62},[1059],{"nctId":1060,"briefTitle":1061,"status":151,"phases":1062,"primaryCompletion":1063,"completion":1064,"start":1065,"enrollment":1066,"conditions":1067,"interventions":1069},"NCT00535379","SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme",[52],"2010-12","2011-01","2007-10",70,[1068],"Glioblastoma Multiforme",[1051],{"trials":1071,"activeCount":62},[],{"trials":1073,"activeCount":62},[],{"trials":1075,"activeCount":62},[],{"intervention":1077,"totalTrials":58,"cells":1078},"Ganetespib",{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1098,"PHASE4":1100,"NA":1102},{"trials":1080,"activeCount":62},[],{"trials":1082,"activeCount":62},[],{"trials":1084,"activeCount":62},[1085],{"nctId":1086,"briefTitle":1087,"status":188,"phases":1088,"primaryCompletion":1089,"completion":1090,"start":1091,"enrollment":1092,"conditions":1093,"interventions":1096},"NCT02012192","GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer",[51,52],"2017-11-30","2017-12-04","2014-07-04",133,[1094,725,1095],"Epithelial Ovarian Cancer","Primary Peritoneal Cancer",[1077,1097],"Paclitaxel",{"trials":1099,"activeCount":62},[],{"trials":1101,"activeCount":62},[],{"trials":1103,"activeCount":62},[],{"intervention":1097,"totalTrials":58,"cells":1105},{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1107,"activeCount":62},[],{"trials":1109,"activeCount":62},[],{"trials":1111,"activeCount":62},[1112],{"nctId":1086,"briefTitle":1087,"status":188,"phases":1113,"primaryCompletion":1089,"completion":1090,"start":1091,"enrollment":1092,"conditions":1114,"interventions":1115},[51,52],[1094,725,1095],[1077,1097],{"trials":1117,"activeCount":62},[],{"trials":1119,"activeCount":62},[],{"trials":1121,"activeCount":62},[],{"intervention":1123,"totalTrials":58,"cells":1124},"68Ga-NeoBOMB1, 2-vial kit",{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1141,"PHASE4":1143,"NA":1145},{"trials":1126,"activeCount":62},[],{"trials":1128,"activeCount":62},[],{"trials":1130,"activeCount":62},[1131],{"nctId":1132,"briefTitle":1133,"status":214,"phases":1134,"primaryCompletion":1135,"completion":1135,"start":1136,"enrollment":1137,"conditions":1138,"interventions":1140},"NCT02931929","MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET\u002FCT",[51,52],"2019-04-09","2016-11-28",9,[1139],"Gastrointestinal Stromal Tumors",[1123],{"trials":1142,"activeCount":62},[],{"trials":1144,"activeCount":62},[],{"trials":1146,"activeCount":62},[],{"intervention":729,"totalTrials":58,"cells":1148},{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1150,"activeCount":62},[],{"trials":1152,"activeCount":62},[],{"trials":1154,"activeCount":62},[1155],{"nctId":719,"briefTitle":720,"status":151,"phases":1156,"primaryCompletion":494,"start":722,"enrollment":723,"conditions":1157,"interventions":1158},[52],[725,726,727],[729,699],{"trials":1160,"activeCount":62},[],{"trials":1162,"activeCount":62},[],{"trials":1164,"activeCount":62},[],{"intervention":1166,"totalTrials":58,"cells":1167},"Pamidronate or Zoledronate",{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1174,"PHASE4":1176,"NA":1178},{"trials":1169,"activeCount":62},[],{"trials":1171,"activeCount":62},[],{"trials":1173,"activeCount":62},[],{"trials":1175,"activeCount":62},[],{"trials":1177,"activeCount":62},[],{"trials":1179,"activeCount":62},[1180],{"nctId":1181,"briefTitle":1182,"status":214,"phases":1183,"primaryCompletion":1184,"start":1185,"enrollment":23,"conditions":1186,"interventions":1190},"NCT02823925","Bisphosphonate Therapy in MONA Spectrum Disorder",[],"2015-01","2013-02",[1187,1188,1189],"Bone Density","Pain","Fracture",[1166],{"intervention":1192,"totalTrials":58,"cells":1193},"Avastin",{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1198,"PHASE3":1200,"PHASE4":1202,"NA":1204},{"trials":1195,"activeCount":62},[],{"trials":1197,"activeCount":62},[],{"trials":1199,"activeCount":62},[],{"trials":1201,"activeCount":62},[],{"trials":1203,"activeCount":62},[],{"trials":1205,"activeCount":62},[1206],{"nctId":1207,"briefTitle":1208,"status":188,"phases":1209,"primaryCompletion":424,"completion":1210,"start":722,"enrollment":298,"conditions":1211,"interventions":1216},"NCT01507740","Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients",[],"2014-10",[1212,1213,1214,1215],"Hepatocellular Cancer","Non-small Cell Lung Cancer","Renal Cell Cancer","Colorectal Cancer",[1192,1217,1218],"Suntent","Nexavar",{"intervention":1217,"totalTrials":58,"cells":1220},{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1227,"PHASE4":1229,"NA":1231},{"trials":1222,"activeCount":62},[],{"trials":1224,"activeCount":62},[],{"trials":1226,"activeCount":62},[],{"trials":1228,"activeCount":62},[],{"trials":1230,"activeCount":62},[],{"trials":1232,"activeCount":62},[1233],{"nctId":1207,"briefTitle":1208,"status":188,"phases":1234,"primaryCompletion":424,"completion":1210,"start":722,"enrollment":298,"conditions":1235,"interventions":1236},[],[1212,1213,1214,1215],[1192,1217,1218],{"intervention":1218,"totalTrials":58,"cells":1238},{"EARLY_PHASE1":1239,"PHASE1":1241,"PHASE2":1243,"PHASE3":1245,"PHASE4":1247,"NA":1249},{"trials":1240,"activeCount":62},[],{"trials":1242,"activeCount":62},[],{"trials":1244,"activeCount":62},[],{"trials":1246,"activeCount":62},[],{"trials":1248,"activeCount":62},[],{"trials":1250,"activeCount":62},[1251],{"nctId":1207,"briefTitle":1208,"status":188,"phases":1252,"primaryCompletion":424,"completion":1210,"start":722,"enrollment":298,"conditions":1253,"interventions":1254},[],[1212,1213,1214,1215],[1192,1217,1218],{"intervention":1256,"totalTrials":58,"cells":1257},"restrictive oxygen supply",{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1264,"PHASE4":1266,"NA":1268},{"trials":1259,"activeCount":62},[],{"trials":1261,"activeCount":62},[],{"trials":1263,"activeCount":62},[],{"trials":1265,"activeCount":62},[],{"trials":1267,"activeCount":62},[],{"trials":1269,"activeCount":62},[1270],{"nctId":1271,"briefTitle":1272,"status":214,"phases":1273,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1276,"conditions":1277,"interventions":1281},"NCT05946707","Effects of Oxygen Supply After Lung Isolation in Thoracic Surgery",[55],"2024-03-07","2023-07-19",55,[1278,1279,1280],"Mechanical Ventilation","Thoracic Surgery","One-Lung Ventilation",[1256,1282],"liberal oxygen supply",{"intervention":1282,"totalTrials":58,"cells":1284},{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1291,"PHASE4":1293,"NA":1295},{"trials":1286,"activeCount":62},[],{"trials":1288,"activeCount":62},[],{"trials":1290,"activeCount":62},[],{"trials":1292,"activeCount":62},[],{"trials":1294,"activeCount":62},[],{"trials":1296,"activeCount":62},[1297],{"nctId":1271,"briefTitle":1272,"status":214,"phases":1298,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1276,"conditions":1299,"interventions":1300},[55],[1278,1279,1280],[1256,1282]]